Prostate Cancer – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Prostate cancer (PCa) is one of the most prevalent malignancies globally. Most men with newly diagnosed PCa present with localized disease and undergo radical prostatectomy and radiological therapy, followed by androgen deprivation therapy (ADT). Depending on the cancer grade, a variable percentage of these patients experience castration-resistant prostate cancer (CRPC) progression within ten years. Metastatic castration-resistant prostate cancer (MCRPC) patients remain incurable, and the prognosis of these patients is relatively poor. For men with CRPC, the median survival ranges from 9 to 30 months, and for those with MCRPC, this survival is reduced to 9–13 months. Currently, cytotoxic chemotherapy agents, AR blocking agents, immunotherapies, and radiopharmaceuticals represent effective therapeutic strategies for MCRPC treatment. Taxane chemotherapy (docetaxel and cabazitaxel) is the standard for MCRPC treatment.

 

Prostate cancer (PCa) incidence ranges from 95 to 112 cases per 100,000 population in the USA, representing ~15% of all cancer patients. ~85% to 90% of patients with new mCRPC issues were from the progression of nmCRPC.

 

The competitive landscape of Prostate Cancer includes country-specific approved and pipeline therapies. Any asset/product-specific designation, review, and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Prostate Cancer across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Prostate Cancer Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Prostate Cancer – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          olaparib plus abiraterone acetate            AstraZeneca     Phase 3

2          AC0176            Accutar Biotechnology   Phase 1

3          SRF617            Surface Oncology          Phase 2

4          Fuzuloparib, Abiraterone acetate, and Prednisone           Jiangsu HengRui Medicine Co., Ltd.       Phase 3

5          Irofulven           Allarity Therapeutics      Phase 2

6          REGN4336       Regeneron Pharmaceuticals      Phase 2

7          VERU-111        Veru Inc.           Phase 3

8          Talazoparib       Medivation, Inc. Phase 2

9          ZEN003694 and Enzalutamide   Zenith Epigenetics         Phase 2

10        Abivertinib and Abiraterone        Sorrento Therapeutics, Inc.            Phase 2

Continued

Comments

Post a Comment

Popular posts from this blog

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more